Welcome to our dedicated page for Insmed news (Ticker: $INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Insmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Insmed's position in the market.
Insmed Incorporated reported total revenue of $75.5 million for the first quarter of 2024, showing 16% growth over the same period in 2023. The company highlighted positive safety and tolerability data from TPIP studies and encouraging results from PAH trials. They reiterated their 2024 revenue guidance of $340-360 million for global ARIKAYCE. Insmed continues to focus on commercial expansion, R&D for brensocatib and TPIP, and early-stage research programs.
Insmed Incorporated (Nasdaq:INSM) will present at the BofA Securities Health Care Conference 2024, aiming to transform the lives of patients with serious and rare diseases. The fireside chat will take place on May 14, 2024, at 2:20 p.m. PT (5:20 p.m. ET) in Las Vegas, NV. The webcast will be accessible on the company's investor relations website for 30 days post-event.
Insmed Incorporated (INSM) granted inducement awards to 63 new employees as a material inducement to their employment. The employees received options to purchase 410,300 shares of Insmed common stock at an exercise price of $25.59 per share. The options have a 10-year term and a four-year vesting schedule.
